Kura Oncology (NASDAQ:KURA) Issues Earnings Results

Kura Oncology (NASDAQ:KURA) posted its quarterly earnings results on Wednesday. The company reported ($0.77) earnings per share for the quarter, beating the consensus estimate of ($0.88) by $0.11, FiscalAI reports. Kura Oncology had a negative return on equity of 141.95% and a negative net margin of 411.19%.The business had revenue of $20.87 million for the quarter, compared to the consensus estimate of $20.16 million.

Here are the key takeaways from Kura Oncology’s conference call:

• KOMZIFTI generated $9.1 million in second-quarter net product revenue, with approximately 115 new patient starts and more than 250 prescriptions. Management said the drug captured a majority of new patient starts in the relapsed/refractory NPM1-mutated AML menin inhibitor market despite launching second.
• KOMZIFTI’s new patient starts increased about 35% sequentially and total prescriptions rose about 60%, while approximately 40% of new starts involved physician-initiated combination use. More than 95% of covered lives have access, including roughly 16 million lives with preferred coverage.
• Clinical data supported ziftomenib’s expansion into frontline AML and combination therapy, including a 94% 12-month overall survival rate in the frontline KOMET-007 dataset. The company expects additional FLT3 combination, long-term venetoclax, and other AML data in the second half of 2026, while pivotal KOMET-017 results remain targeted for 2028.
• Kura ended the quarter with $519 million in cash and short-term investments, down from $667.2 million at year-end 2025, and reported a $68.3 million net loss. Management said available funds plus expected Kyowa Kirin payments should fund the ziftomenib program through 2028, but further development of darlifarnib and potential registrational studies could require disciplined capital allocation or additional financing.
• Darlifarnib produced encouraging early combination data, including a 44% response rate in cabozantinib-exposed renal cell carcinoma and tumor shrinkage in 77% of response-evaluable patients receiving adagrasib in KRAS G12C-mutated cancers. A randomized renal cell carcinoma study is expected to complete enrollment in the first half of 2027, with initial data anticipated in the second half.

Kura Oncology Trading Up 0.1%

NASDAQ KURA traded up $0.01 on Wednesday, reaching $9.94. 1,133,321 shares of the company were exchanged, compared to its average volume of 1,551,765. Kura Oncology has a fifty-two week low of $6.24 and a fifty-two week high of $12.49. The stock has a market capitalization of $882.41 million, a P/E ratio of -2.97 and a beta of 0.38. The business’s fifty day moving average price is $10.12 and its 200 day moving average price is $9.31. The company has a current ratio of 6.15, a quick ratio of 6.14 and a debt-to-equity ratio of 0.09.

Insider Buying and Selling at Kura Oncology

In related news, insider Mollie Leoni sold 84,929 shares of the company’s stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $9.82, for a total value of $834,002.78. Following the completion of the sale, the insider owned 182,345 shares of the company’s stock, valued at approximately $1,790,627.90. This represents a 31.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 7.60% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in KURA. Virtu Financial LLC acquired a new stake in shares of Kura Oncology during the 4th quarter worth about $349,000. Invesco Ltd. boosted its stake in Kura Oncology by 14.6% during the fourth quarter. Invesco Ltd. now owns 209,370 shares of the company’s stock worth $2,175,000 after buying an additional 26,683 shares during the period. Mercer Global Advisors Inc. ADV raised its stake in shares of Kura Oncology by 52.3% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 50,080 shares of the company’s stock valued at $520,000 after acquiring an additional 17,197 shares during the period. Voloridge Investment Management LLC purchased a new stake in shares of Kura Oncology in the 4th quarter valued at approximately $2,505,000. Finally, Virtus Investment Advisers LLC lifted its holdings in shares of Kura Oncology by 291.4% in the 4th quarter. Virtus Investment Advisers LLC now owns 66,870 shares of the company’s stock worth $695,000 after acquiring an additional 49,785 shares during the last quarter.

Analysts Set New Price Targets

Several equities research analysts have weighed in on KURA shares. CLSA set a $24.00 price target on Kura Oncology in a research report on Thursday, June 4th. Jefferies Financial Group set a $24.00 target price on Kura Oncology in a research report on Thursday, May 28th. Wells Fargo & Company set a $24.00 price target on shares of Kura Oncology in a research note on Thursday, June 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Kura Oncology in a research note on Friday, July 17th. Finally, Lake Street Capital started coverage on Kura Oncology in a report on Tuesday, April 14th. They issued a “buy” rating and a $23.00 price objective on the stock. Ten analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $25.46.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.